ISSN (On-line) 1678-2925
Home
About
Brief History
Open Science Compliance
Publication Ethics
Focus and Scope
Digital Preservation
Editorial Policy
Ethics Committee
Copyright License
Issues
Current Issue
Previous
Supplements
Ahead of print
COMMENTED PAPERS - EDITORS CHOICE
Advanced Search
Editorial Board
Submission
Instructions to Authors
Submission of articles
Required Documents
Editorial Responsibilities
Charges Fees
Conflict of interest
Media
Videos
Podcasts
Contact
Home
Past Issues
Summary Vol.84 Issue
3 / 2021
Article
Original Articles
Views
Arq. Bras. Oftalmol. 2021; 84 (3):
Total:
2965
Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results
Related content
Statistics
About the authors
Article
Submission is temporarily unavailable. reCAPTCHA validation has not been configured yet.
Message
Name
E-mail
will not be published
This article not yet has been commented, be the first!
PDF English
Print
Share
▼
Send this article by email
Submit a comment
Mendeley
Pocket
Share on Facebook
Share on Twitter
Share on Linkedin
Share on WhatsApp
How to cite this article:
Mudança de tratamento para o aflibercepte no tratamento da Degeneração Macular neovascular Relacionada à Idade: resultados de 30 meses. Arq. Bras. Oftalmol. 2021;84(3):.
Export citation
ABO is licensed under a Creative Commons Attribution-NonComercial 4.0 Internacional.
